[go: up one dir, main page]

WO2013032231A3 - Composition pharmaceutique anti-angiogène comprenant un inhibiteur de microarn-382 - Google Patents

Composition pharmaceutique anti-angiogène comprenant un inhibiteur de microarn-382 Download PDF

Info

Publication number
WO2013032231A3
WO2013032231A3 PCT/KR2012/006910 KR2012006910W WO2013032231A3 WO 2013032231 A3 WO2013032231 A3 WO 2013032231A3 KR 2012006910 W KR2012006910 W KR 2012006910W WO 2013032231 A3 WO2013032231 A3 WO 2013032231A3
Authority
WO
WIPO (PCT)
Prior art keywords
microrna
inhibitor
angiogenic composition
composition including
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/006910
Other languages
English (en)
Korean (ko)
Other versions
WO2013032231A2 (fr
Inventor
이유미
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of KNU
Original Assignee
Industry Academic Cooperation Foundation of KNU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of KNU filed Critical Industry Academic Cooperation Foundation of KNU
Priority to US14/240,539 priority Critical patent/US9012426B2/en
Priority claimed from KR20120094794A external-priority patent/KR20130024831A/ko
Publication of WO2013032231A2 publication Critical patent/WO2013032231A2/fr
Publication of WO2013032231A3 publication Critical patent/WO2013032231A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition anti-angiogène et plus particulièrement une composition pharmaceutique anti-angiogène comprenant un inhibiteur de microARN-382. Les inventeurs de la présente invention ont confirmé que le micro-ARN-382 dont l'expression est élevée dans les cellules du cancer de l'estomac dans des environnements pauvres en oxygène, modifie la promotion de l'angiogenèse induite par un environnement pauvre en oxygène. Ainsi, la composition pharmaceutique de l'invention inhibe le microARN-382 et donc l'angiogenèse et la prolifération cellulaire, et peut finalement être utilisé de manière avantageuse dans le traitement du cancer.
PCT/KR2012/006910 2011-08-30 2012-08-29 Composition pharmaceutique anti-angiogène comprenant un inhibiteur de microarn-382 Ceased WO2013032231A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/240,539 US9012426B2 (en) 2011-08-30 2012-08-29 Pharmaceutical anti-angiogenic composition including a MicroRNA-382 inhibitor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2011-0086987 2011-08-30
KR20110086987 2011-08-30
KR10-2012-0094794 2012-08-29
KR20120094794A KR20130024831A (ko) 2011-08-30 2012-08-29 ｍｉｃｒｏＲＮＡ－382의 억제제를 포함하는 혈관신생억제용 약학적 조성물

Publications (2)

Publication Number Publication Date
WO2013032231A2 WO2013032231A2 (fr) 2013-03-07
WO2013032231A3 true WO2013032231A3 (fr) 2013-05-10

Family

ID=47757054

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/006910 Ceased WO2013032231A2 (fr) 2011-08-30 2012-08-29 Composition pharmaceutique anti-angiogène comprenant un inhibiteur de microarn-382

Country Status (1)

Country Link
WO (1) WO2013032231A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014008A2 (fr) * 2006-07-28 2008-01-31 The Johns Hopkins University Compositions et procédés pour moduler l'angiogenèse
KR20100009268A (ko) * 2008-07-18 2010-01-27 국립암센터 마이크로ｒｎａ분자를 포함하는 항암 조성물
US20110184043A1 (en) * 2008-04-07 2011-07-28 Cornell Research Foundation, Inc. Inhibition of angiogenesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014008A2 (fr) * 2006-07-28 2008-01-31 The Johns Hopkins University Compositions et procédés pour moduler l'angiogenèse
US20110184043A1 (en) * 2008-04-07 2011-07-28 Cornell Research Foundation, Inc. Inhibition of angiogenesis
KR20100009268A (ko) * 2008-07-18 2010-01-27 국립암센터 마이크로ｒｎａ분자를 포함하는 항암 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM, MIN JEONG: "The roles of microRNA-382 induced by hypoxia in angiogenesis master's thesis", KYUNKPOOK NATIONAL UNIVERSITY GRADUATE SCHOOL, June 2010 (2010-06-01) *

Also Published As

Publication number Publication date
WO2013032231A2 (fr) 2013-03-07

Similar Documents

Publication Publication Date Title
IN2015DN03795A (fr)
TN2012000280A1 (en) Methods of administering pirfenidone therapy
MY188363A (en) Substituted tricyclic compounds as fgfr inhibitors
MX367795B (es) Inhibidores de cdk.
WO2012104007A3 (fr) Dérivés de 7-azaindole
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
TW201711676A (en) Ferric citrate dosage forms
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
PH12014501032A1 (en) 2-thiopyrimidinones
JO3419B1 (ar) مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr
IN2014DN06104A (fr)
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EP4582090A3 (fr) Composition comprenant de l'arginine déiminase pégylée
WO2012065139A3 (fr) Inhibiteurs de entpd5
GB2502032A (en) Vitamin D composition
MX2012001306A (es) Inhibicion de matastasis de tumor.
NZ711564A (en) Methods of treating colorectal cancer
MX2013001793A (es) Producto para la esfera gastrica superior.
WO2010030835A3 (fr) Compositions pharmaceutiques à base d'un inhibiteur de la src kinase et d'un inhibiteur de l'aromatase
TR201009167A2 (tr) Sefalosporin içeren farmasötik granüller.
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
WO2013032231A3 (fr) Composition pharmaceutique anti-angiogène comprenant un inhibiteur de microarn-382
EP2920311A4 (fr) Procédés et compositions pour le traitement de biomasse ayant des taux élevés d'amidon
MX2013005699A (es) Composiciones de interferon-beta estables conservadas.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12828326

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14240539

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12828326

Country of ref document: EP

Kind code of ref document: A2